CXCL12 and cancer: Since CXCR4 and CXCR7 are both involved in cancer malignancy, and in particular in GBM angiogenesis, molecules able to interact and block either CXCL12 itself or both receptors simultaneously could represent an improved pharmacological approach (Duda et al., 2011; Singh et al., 2013).